December 19, 2006 - 4:32 p.m.
Gilead Announces Preliminary Results From Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Printer Friendly Version 
December 18, 2006 - 4:17 p.m.
Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
Printer Friendly Version 
December 15, 2006 - 8:34 a.m.
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
Printer Friendly Version 
December 11, 2006 - 4:03 p.m.
Gilead Grants Intellectual Property Rights for Tenofovir Topical Gel to the International Partnership for Microbicides and CONRAD
Printer Friendly Version 
December 07, 2006 - 7:57 p.m.
Gilead Sciences Receives Subpoena from U.S. Department of Justice
Printer Friendly Version 
December 01, 2006 - 4:32 p.m.
Gilead Sciences to Present at the NASDAQ 18th Investor Program on Thursday, December 7
Printer Friendly Version 
November 22, 2006 - 4:33 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
November 17, 2006 - 4:04 p.m.
Gilead Sciences Completes Acquisition of Myogen
Printer Friendly Version 
November 14, 2006 - 4:32 p.m.
Gilead Sciences to Present at the Credit Suisse Healthcare Conference on Friday, November 17th
Printer Friendly Version 
November 14, 2006 - 8:31 a.m.
Gilead Sciences Successfully Completes Tender Offer for Shares of Myogen With Over 91.3 Percent of Shares Tendered
Printer Friendly Version 
November 03, 2006 - 4:02 p.m.
Gilead Sciences Completes Acquisition of Raylo Chemicals Inc.
Printer Friendly Version 
November 01, 2006 - 6:29 p.m.
Gilead Sciences Extends Expiration Date for Tender Offer for Myogen Until November 13, 2006
Printer Friendly Version 
October 26, 2006 - 4:03 p.m.
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Printer Friendly Version 
October 18, 2006 - 4:02 p.m.
Gilead Sciences Announces Third Quarter 2006 Financial Results
Printer Friendly Version 
October 13, 2006 - 4:32 p.m.
Gilead Sciences to Release Third Quarter 2006 Financial Results on Wednesday, October 18, 2006
Printer Friendly Version 
October 09, 2006 - 2:32 a.m.
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Printer Friendly Version 
October 02, 2006 - 7:03 a.m.
Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion
Printer Friendly Version 
September 28, 2006 - 7:59 p.m.
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
Printer Friendly Version 
September 27, 2006 - 8:33 a.m.
Landmark Five-Year Data on Gilead's Anti-HIV Drug Viread(R) Presented at 8th International Workshop on Adverse Drug Reactions and Lipodystrophy
Printer Friendly Version 
September 22, 2006 - 4:02 p.m.
Gilead Announces Licensing Agreements with Eight India-Based Companies for Manufacturing and Distribution of Generic Versions Of Viread in the Developing World
Printer Friendly Version 
September 21, 2006 - 4:17 p.m.
Gilead Sciences to Present at The UBS Global Life Sciences Conference on Monday, September 25th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
September 08, 2006 - 4:17 p.m.
Gilead Sciences to Present at the Bear Stearns 19th Annual Healthcare Conference on Tuesday, September 12th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
September 01, 2006 - 4:17 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
August 30, 2006 - 4:17 p.m.
Gilead Sciences' President and Chief Executive Officer Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
August 14, 2006 - 4:17 p.m.
Gilead Announces Licensing Agreements with Three India-Based Companies for Manufacturing and Distribution of Generic Versions of Viread in the Developing World
Printer Friendly Version 
August 14, 2006 - 9:02 a.m.
96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference
Printer Friendly Version 
August 11, 2006 - 4:16 p.m.
Gilead Sciences Completes Acquisition of Corus Pharma
Printer Friendly Version 
August 11, 2006 - 4:07 p.m.
Gilead Sciences and Merck Establish Agreement for Distribution of ATRIPLA(TM) in Developing Countries
Printer Friendly Version 
August 02, 2006 - 4:02 p.m.
Gilead Sciences Exercises Option to Acquire Corus Pharma for $365 Million
Printer Friendly Version 
July 20, 2006 - 4:03 p.m.
Gilead Sciences Announces Second Quarter 2006 Financial Results
Printer Friendly Version 
July 19, 2006 - 4:16 p.m.
Gilead Sciences Agrees to Exercise Its Option to Acquire Corus Pharma for $365 Million
Printer Friendly Version 
July 14, 2006 - 4:32 p.m.
Gilead Sciences to Release Second Quarter 2006 Financial Results on Thursday, July 20, 2006; Conference Call and Webcast to Follow
Printer Friendly Version 
July 13, 2006 - 4:47 a.m.
Gilead Sciences and the Institute of Organic Chemistry and Biochemistry (IOCB) Establish New Academic Research Centre in Prague; Donation by Gilead Honors Leadership of Dr. Antonin Holy in Antiviral Drug Discovery and Development
Printer Friendly Version 
July 12, 2006 - 1:54 p.m.
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Printer Friendly Version 
June 23, 2006 - 4:32 p.m.
Gilead Sciences to Present at the William Blair & Company 26th Annual Growth Stock Conference on Wednesday, June 28th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
June 09, 2006 - 4:32 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
June 06, 2006 - 8:33 a.m.
Gilead Sciences to Acquire Degussa's Raylo Chemicals Inc.; Purchase to Expand Gilead's Manufacturing Scale-Up Capacity for Investigational Therapies
Printer Friendly Version 
May 26, 2006 - 4:32 p.m.
Gilead Sciences to Present at the 22nd Annual Sanford Bernstein Strategic Decisions Conference 2006 on Wednesday, May 31st; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
May 16, 2006 - 8:33 a.m.
Gilead Announces Dismissal of Securities Litigation
Printer Friendly Version 
May 12, 2006 - 4:32 p.m.
Gilead Sciences to Present at the Banc of America 2006 Health Care Conference on Thursday, May 18th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
May 10, 2006 - 12:49 p.m.
Gilead Offers Voluntary Licenses for Manufacturing of Viread in Developing World
Printer Friendly Version 
April 28, 2006 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
April 27, 2006 - 7:27 a.m.
Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment
Printer Friendly Version 
April 25, 2006 - 8:32 a.m.
Gilead Closes Sale of $1.3 Billion Convertible Senior Notes
Printer Friendly Version 
April 20, 2006 - 8:30 a.m.
Gilead Prices $1.2 Billion Convertible Senior Notes; Company to Repurchase Approximately $545 Million in Common Stock
Printer Friendly Version 
April 18, 2006 - 4:04 p.m.
Gilead to Offer $1.1 Billion Convertible Senior Notes; Company to Repurchase Approximately $500 Million in Common Stock
Printer Friendly Version 
April 18, 2006 - 4:02 p.m.
Gilead Sciences Announces First Quarter 2006 Financial Results
Printer Friendly Version 
April 14, 2006 - 4:02 p.m.
Gilead Sciences to Release First Quarter 2006 Financial Results on Tuesday, April 18, 2006; Conference Call and Webcast to Follow
Printer Friendly Version 
April 12, 2006 - 4:02 p.m.
Gilead Invests $25 Million in Corus Pharma; Establishes Equity Position in Company With Late-Stage Product Candidate for Cystic Fibrosis
Printer Friendly Version 
April 06, 2006 - 8:33 a.m.
Kristen M. Metza Joins Gilead as Vice President, Human Resources
Printer Friendly Version 
March 08, 2006 - 9:31 a.m.
U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada(R) and Viread(R); 48-Week Data from Pivotal Study 934 Added to U.S. Prescribing Information for Both Products
Printer Friendly Version 
March 03, 2006 - 7:19 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 24, 2006 - 4:32 p.m.
Gilead Sciences to Present at the Citigroup 2006 Healthcare Conference on Tuesday, February 28th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
February 10, 2006 - 9:17 a.m.
Gilead Sciences Launches Stop Hep B Campaign; Initiative Aims to Combat Chronic Hepatitis B by Educating and Empowering At-Risk Communities
Printer Friendly Version 
February 09, 2006 - 1:02 p.m.
Gilead Announces Results from Phase I/II Study of Investigational HIV Integrase Inhibitor GS 9137
Printer Friendly Version 
February 07, 2006 - 9:16 a.m.
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Wednesday, February 8th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
February 06, 2006 - 7:04 p.m.
Gilead Sciences' Board Member Amends Existing Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
January 30, 2006 - 4:02 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2005 Financial Results
Printer Friendly Version 
January 23, 2006 - 9:02 a.m.
Gilead Sciences to Release Fourth Quarter and Year End 2005 Financial Results on Monday, January 30, 2006; Conference Call and Webcast to Follow
Printer Friendly Version 
January 18, 2006 - 5:02 p.m.
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine
Printer Friendly Version 
January 09, 2006 - 9:18 a.m.
Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial
Printer Friendly Version 
January 09, 2006 - 9:12 a.m.
Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate)
Printer Friendly Version 
January 06, 2006 - 4:37 p.m.
Gilead Sciences to Present at the 24th Annual JPMorgan Healthcare Conference on Monday, January 9th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
NASDAQ (US Dollar)
$67.49
 Stock is Down 0.34 (0.50%)
Data as of 03/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote